Dermal filler safety, explained for patients

What hyaluronic acid filler is

Hyaluronic acid is a sugar the body already makes; it holds water in skin and joints. In a filler, chains of hyaluronic acid are cross-linked into a smooth gel so that the body breaks it down more slowly than its own hyaluronic acid. Most hyaluronic acid used in fillers is made by bacterial fermentation, not taken from animals.

The FDA regulates dermal fillers as medical device implants, and its patient guidance says filler injection should be considered a medical procedure, not a cosmetic treatment. The gel is absorbed over time, so results are temporary and treatment is repeated to maintain them.

The articles in this section cover the whole range of what can happen after filler, from the expected to the very rare. The dermal fillers service page describes how treatment is planned here; the safety page describes how complications are prepared for.

Expected effects

Every injection causes some trauma. The FDA lists bruising, redness, swelling, pain, tenderness, itching and rash as the common side effects, and notes that most common side effects, such as swelling and bruising, occur shortly after injection and many resolve in a few days to weeks ^{(source, verified Nov 2026)}. In the literature, most post-injection swelling caused by the needle trauma itself settles within one week ^{(source, verified Nov 2026)}, and a bruise may appear at once or get darker over the first three days ^{(source, verified Nov 2026)}. None of these is a complication. They are the body responding to a needle and to a new material.

Lips swell more than most areas. How long lip filler swelling lasts, and when it is a warning sign covers the normal course in detail.

Uncommon effects

Lumps and nodules

A lump that can be felt in the first weeks is usually filler that has not yet settled, or swelling around it, and most resolve or can be smoothed. In the literature, early implant nodules tend to show up within about two to four weeks ^{(source, verified Nov 2026)}, while delayed-onset nodules appear from four weeks to a year or more after treatment and are usually inflammatory or infection-related ^{(source, verified Nov 2026)}. True granulomas, the body walling off the material, are a different and less common event: true foreign-body granulomas are rare, with an estimated incidence between 0.01 and 1 percent ^{(source, verified Nov 2026)}. A nodule that appears months after treatment, or that is red, tender or growing, needs assessment rather than waiting.

The Tyndall effect

When hyaluronic acid filler sits too close to the surface, light scattering through the skin can give the area a bluish tint. This is a placement problem, not a reaction. Hyaluronidase is the first treatment, and left untreated, the bluish discoloration can last for years ^{(source, verified Nov 2026)}.

Migration

Filler can move from where it was placed. It is listed among the delayed events in the literature and is more likely in mobile areas such as the lips. Most often the result is a cosmetic one, a soft fullness above the lip border for example, and hyaluronic acid filler that has moved can be dissolved.

Infection and cold sores

Infection after filler is rare and tends to appear days later as spreading redness, warmth, increasing pain or drainage. A needle through the lip can also reactivate cold sores in people who get them: cold sores recurred in about 0.6 percent of people in a pooled analysis of lip filler studies ^{(source, verified Nov 2026)}. That history is asked about at the Good Faith Exam, because a preventive antiviral can be prescribed.

The rare serious complication: a blocked artery

If filler is injected into an artery, or a bolus presses on one, the skin that artery feeds loses its blood supply. This is a vascular occlusion. Unrecognised, it can lead to tissue death and scarring. If the filler travels into the arteries that also supply the eye, it can cause vision loss. The FDA lists necrosis, vision abnormalities including blindness, and stroke among the serious complications reported after filler was unintentionally injected into a blood vessel.

Two things follow from the numbers. First, an occlusion is rare, and in the dermatologist survey most of those that did occur resolved without lasting harm. Second, where the injection happens matters a great deal: the nose, the glabella (between the brows) and the forehead were the most common injection sites in reported vision-loss cases, and the review found no published vision-loss cases from the lips, tear troughs, jawline or chin ^{(source, verified Nov 2026)}. That is why the nose, glabella and forehead are treated as the highest-risk zones, and why the lips, though a common site for occlusions of the skin, have not been linked to published vision loss.

What a vascular occlusion is, what the warning signs are, and how it is treated is written for anyone who has had filler and wants to know what to watch for.

How a careful injector lowers the risk

No technique removes the risk. What follows is what the guidelines and the literature support.

Knowing the anatomy

Guidelines ask injectors to grade every area by vascular risk and never to call any area safe. The glabella, nose and forehead are graded very high risk; previous surgery or scarring in an area raises the risk further because vessels may not run where expected. Placing filler deep on the bone, below the plane where the main arteries run, is a strategy that depends on knowing where the bone and the vessels are in the person in the chair, not in a diagram.

The aspiration debate, stated plainly

Aspiration means pulling back on the syringe plunger before injecting, to see whether blood flashes back and the needle tip is in a vessel. Many consensus documents and product labels still describe it. A review in Aesthetic Surgery Journal concluded that it cannot be relied on as a safety measure: filler gels are too thick to flash back quickly, a vessel can collapse under suction, and the hand moves between the pull-back and the injection. The CMAC guideline on managing occlusions puts the same point with numbers: reported reliability of aspiration ranges from 33 to 63 percent, and a negative result does not rule out a vessel ^{(source, verified Nov 2026)}. An earlier expert consensus, by contrast, still lists aspiration among its preventive steps. The honest summary is that a negative aspiration is weak reassurance, and that the practices below carry more of the weight.

Cannula versus needle

A cannula is a blunt-tipped tube that is threaded under the skin from a single entry point, rather than a sharp needle that is placed at each site. In a retrospective survey of US dermatologists, cannula injections were associated with about 77 percent lower odds of an occlusion than needle injections ^{(source, verified Nov 2026)}, the figures quoted in the Numbers callout above. The same study and the CMAC guideline are clear that both instruments have caused occlusions. CMAC advises avoiding cannulas finer than 25 gauge, because very thin cannulas can pierce a vessel much as a needle does ^{(source, verified Nov 2026)}, and the aspiration review notes that the nose is not an area where a cannula should be assumed safer.

Slow, low pressure, small amounts

Guidelines agree on this more than on anything else. Injecting slowly, with the least pressure that moves the gel, in small amounts per site, limits how much filler could enter a vessel before a problem is noticed. The aspiration review recommends micro-boluses of less than 0.1 mL per placement ^{(source, verified Nov 2026)}. The CMAC guideline also advises against mixing adrenaline into local anesthetic for filler, because the whitening it causes can hide the whitening of an occlusion.

Watching the skin and listening to the patient

Capillary refill is the simplest check: press on the skin, release, and watch the color come back. In the CMAC guideline, color normally returns in under two seconds ^{(source, verified Nov 2026)}, and the check is done on both sides of the face so there is a comparison. Injectors are asked to watch for color change throughout and to tell patients to report any sudden pain, or any change in vision, the moment it happens. The safety page describes how this is done at Tanya’s appointments.

Being ready

The CMAC guideline expects every practice that injects hyaluronic acid filler to have a written management plan, hyaluronidase to hand, and adrenaline available for the rare allergic reaction to it. A plan that has been rehearsed is faster than one that is looked up.

Reversal with hyaluronidase

Hyaluronidase is an enzyme that breaks the bonds in hyaluronic acid. Injected into filler, it dissolves the gel over hours. It is used electively, to soften or remove a result, and urgently, to clear a blocked vessel, where it is the one treatment with direct evidence behind it.

Two things patients should know. First, in the United States, using hyaluronidase to dissolve cross-linked hyaluronic acid filler is an off-label use, and the consent conversation should say so ^{(source, verified Nov 2026)}. Second, it is a protein and can cause an allergic reaction; in the CMAC hyaluronidase guideline the risk of anaphylaxis is described as extremely small, lower than the often-quoted 0.1 percent ^{(source, verified Nov 2026)}. People with a history of severe reactions to bee or wasp stings should mention it, because the guideline flags that history. After elective dissolving, the guideline recommends waiting a minimum of two weeks before placing new filler in a dissolved area ^{(source, verified Nov 2026)}.

Hyaluronidase does not act on fillers made of other materials. The FDA notes that some fillers may be difficult or impossible to remove. That is a reason to ask what is in the syringe.

What Arizona requires

Filler is a prescription medical device, and in Arizona the rules for who may inject it are set by the Arizona State Board of Nursing in its advisory opinion on medical aesthetic procedures. Under that opinion, dermal fillers are a Level III advanced procedure that only a registered nurse or an advanced practice registered nurse may perform, under the medical supervision of a licensed independent practitioner with medical or surgical training ^{(source, verified Nov 2026)}. The Board’s term is “licensed independent practitioner”; this site calls the same person the delegating prescriber.

Three requirements matter most to a patient. before any Level II or Level III treatment, a qualified licensed practitioner should perform an initial face-to-face examination of the patient, and telemedicine may be used for that exam ^{(source, verified Nov 2026)}. This is the Good Faith Exam, explained in Arizona’s rules for nurse injectors. Next, an order from a licensed practitioner is required to start any Level II or Level III procedure, and written informed consent is required for Level III ^{(source, verified Nov 2026)}. Finally, the supervising practitioner must be licensed in Arizona, available by telecommunication for consultation and referral, and able to assess the patient within a medically reasonable timeframe when the nurse or the patient asks ^{(source, verified Nov 2026)}, and the practice must keep written protocols, approved by that practitioner, that include guidance on responding to adverse effects ^{(source, verified Nov 2026)}.

A practice that follows these rules can tell you who its prescriber is, arranges the exam before your first treatment, and has a written plan for the rare day something goes wrong. A practice that offers to inject a new patient with no prescriber contact is describing a shortcut.